Obeticholic Acid 5 mg

DRUG3 trials

Sponsors

Intercept Pharmaceuticals, Assiut University

Conditions

Hepatitis B VirusPrimary Biliary CholangitisSteatosis

Phase 2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

CompletedNCT05239468

Intercept PharmaceuticalsPrimary Biliary Cholangitis

Start: 2022-03-21End: 2025-09-01Updated: 2025-09-25

Phase 3

Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes

Not yet recruitingNCT06691412

Assiut UniversityHepatitis B Virus, Steatosis

Start: 2024-11-15End: 2026-03-01Target: 100Updated: 2024-11-15

Unknown Phase

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

WithdrawnNCT05293938

Intercept PharmaceuticalsPrimary Biliary Cholangitis

Start: 2022-03-28End: 2023-07-31Updated: 2023-10-10